Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat

Launched by NORTHWESTERN UNIVERSITY · Sep 13, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments for reducing upper back fat: cryolipolysis and ATX-101 (which is a type of injectable medicine). Cryolipolysis, often known as "fat freezing," involves cooling fat cells to help them break down, while ATX-101 is an injection that helps dissolve fat. Participants in the study will have both sides of their upper back treated, with one side receiving cryolipolysis and the other side getting ATX-101. This trial aims to see which treatment works better for reducing upper back fat.

To join the study, participants must be at least 18 years old and in good health, with mild to moderate upper back fat. They should also be able to understand and agree to participate in the study. Unfortunately, people with certain medical conditions, pregnant or breastfeeding individuals, and those unable to follow instructions won't be eligible. If someone qualifies, they can expect to receive one of the treatments and will be monitored for results. This study is currently active but not recruiting new participants at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males or females ≥ 18 years old
• • 2. Subjects are in good health as judged by the investigator.
• • 3. Subjects with mild to moderate upper back fat.
• • 4. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.
• Exclusion Criteria:
• • 1. History of hypertrophic scars or keloids
• • 2. Subjects currently under treatment with an antiplatelet or anticoagulant for any medical problem or patients who have coagulation disorder
• • 3. Subjects who have a known history of cold-induced disease such as cryoglobulinemia, paroxysmal cold hemoglobulinuria, cold urticaria.
• • 4. Pregnant or breast feeding
• • 5. Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
• • 6. Subjects who are unable to understand the protocol or give informed consent.